Pacific Biosciences
PACB
118 hedge funds and large institutions have $590M invested in Pacific Biosciences in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 8 closing their positions.
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
78% more capital invested
Capital invested by funds: $331M → $590M (+$259M)
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
19% more funds holding
Funds holding: 99 → 118 (+19)
3.82% more ownership
Funds ownership: 70.68% → 74.5% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
40% less call options, than puts
Call options by funds: $627K | Put options by funds: $1.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$17.9M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$11M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.76M |
| 4 |
RI
RTW Investments
New York
|
+$9.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$20.2M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.21M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.56M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.36M |
| 5 |
UM
Ulysses Management
New York
|
-$791K |
PACB Hedge Fund Activity: Q3 2018 in Review
118 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2018, worth a combined $590M — up 78% from $331M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PACB positions and 8 closed out — a net gain of 19 holders — while 35 added to existing stakes and 29 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $17.9M. The largest seller was Capital World Investors, cutting an estimated $20.2M.
- 118 institutional investors held Pacific Biosciences (PACB) as of Q3 2018, up from 99 in Q2 2018.
- Funds reported $590M of Pacific Biosciences stock for Q3 2018, up 78% quarter-over-quarter.
- 27 funds opened new Pacific Biosciences positions in Q3 2018 and 8 closed out, a net change of +19 holders.
- The largest Pacific Biosciences buyer in Q3 2018 was Capital International Investors, an estimated $17.9M added.
- The largest Pacific Biosciences seller in Q3 2018 was Capital World Investors, an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2018.